COMPANY

Epibone, Inc.

Also known as EpiBone · 2 sources

Keywords: tissue engineering Chondral Defect Osteochondral Defect Mandible Tumor Mandibular Injuries EB-CMF

Profile checked Oct 10, 2026

Funding and NIH signals

SEC Form D raise Raised $4.29M (Form D filed Oct 24, 2025). SEC Form D 0001798436-25-000003 (Oct 24, 2025)
Evidence (1 event)
- Oct 24, 2025 · SEC Form D 0001798436-25-000003
  Name of Issuer: EpiBone, Inc.; CIK: 1798436; Address: New York, NY; Submission type: D; Filing date: 2025-10-24; Industry Group: Other; Date of First Sale: 2025-09-02; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 4300506; Total Amount Sold: 4287429; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Jan 1, 2026 Trial start Phase 1/Phase 2: EB-OC for the Treatment of Focal Chondral/Osteochondral Defects in the Knee source ↗
Mar 31, 2021 Trial start Phase 1/Phase 2: Evaluation of EpiBone-CMF for Mandibular Ramus Reconstruction source ↗

Dec 31, 2027 (ESTIMATED) · Phase 1/Phase 2 · EB-OC for the Treatment of Focal Chondral/Osteochondral Defects in the Knee · NCT06895889

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT06895889	EB-OC for the Treatment of Focal Chondral/Osteochondral Defects in the Knee	Phase 1/Phase 2	Not yet recruiting	Jan 1, 2026	Dec 31, 2027 (estimated)
NCT03678467	Evaluation of EpiBone-CMF for Mandibular Ramus Reconstruction	Phase 1/Phase 2	Unknown status (ClinicalTrials.gov)	Mar 31, 2021	2023-08 (estimated)